Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
Clinical Pharmacology and Therapeutics|February 18, 2026
Accelerating Generic Long-Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to AccessUsman Arshad, Lobna Gaayeb, Henry Pertinez, et al.
Southern African Journal of HIV Medicine|March 24, 2018
South African HIV self-testing policy and guidance considerationsFrancois Venter, Mohammed Majam, Lauren Jankelowitz, et al.
The Lancet. HIV|December 4, 2018
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling studyAndrew N Phillips, Francois Venter, Diane Havlir, et al.
The Lancet. HIV|June 11, 2026
Guidance on the clinical management of HIV-1 persistent low-level viraemia on antiretroviral treatment: a scoping review and an international Delphi consensusTommaso Clemente, Arjen J Stam, Olof Elvstam, et al.
The Lancet. HIV|August 19, 2024
The long wait for long-acting HIV prevention and treatment formulationsWillem Daniel Francois Venter, Monica Gandhi, Simiso Sokhela, et al.
The Lancet. HIV|February 9, 2020
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelinesAndrew N Phillips, Loveleen Bansi-Matharu, Francois Venter, et al.
AIDS (London, England)|November 22, 2024
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in AfricaEmmanuelle Papot, Tamara Tovar-Sanchez, Joana Woods, et al.
Global Health, Epidemiology and Genomics|October 20, 2022
Coronavirus Host Genomics Study: South Africa (COVIGen-SA)Andrew K May, Heather Seymour, Harriet Etheredge, et al.
The Lancet. HIV|January 15, 2023
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling studyJennifer Smith, Loveleen Bansi-Matharu, Valentina Cambiano, et al.
The Lancet. HIV|August 7, 2025
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi processChloe Orkin, Amy Paterson, Alexa Elias, et al.
Pageof 15